-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 11, according to foreign media reports, the British Medicines and Health Products Administration granted Eli Lilly’s Retsevmo a conditional marketing license for the treatment of RET fusion-positive advanced lung cancer and thyroid cancer.
In particular, the authorization includes Restevmo (Selpercatinib) as the only treatment option for patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic treatment before receiving immunotherapy and/or platinum-based chemotherapy.
It also includes adults with advanced RET fusion-positive thyroid cancer who need systemic treatment after Sorafenib/Lenvatinib treatment, and adults with advanced RET-mutant medullary thyroid cancer (MTC) 12 years of age and older who need systemic treatment after treatment.
The UK Medicines and Healthcare Products Administration’s approval is based on the results of the LIBRETTO-00 Phase I/II trial, a single-arm study of more than 700 patients with RET-driven cancer.
The preliminary analysis included 105 patients who had previously been treated for non-small cell lung cancer (NSCLC), of which 64% were effective for the treatment, with an average validity period of 17.
Christie’s NHS Foundation Trust’s oncology consultant Yvonne Summers said: “This is good news for RET-driven cancer patients, because they will soon have a treatment option that directly targets RET changes.
RET fusion-positive tumors occur in 1-2% of non-small cell lung cancer (NSCLC) patients, and are more common in people under 60 years of age.